ES2572148T3 - Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados - Google Patents

Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados

Info

Publication number
ES2572148T3
ES2572148T3 ES06770637T ES06770637T ES2572148T3 ES 2572148 T3 ES2572148 T3 ES 2572148T3 ES 06770637 T ES06770637 T ES 06770637T ES 06770637 T ES06770637 T ES 06770637T ES 2572148 T3 ES2572148 T3 ES 2572148T3
Authority
ES
Spain
Prior art keywords
dnj
derivative
pompe disease
carbon atoms
deoxinojirimycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06770637T
Other languages
English (en)
Inventor
Benjamin Mugrage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of ES2572148T3 publication Critical patent/ES2572148T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un derivado de 1-desoxinojirimicina (DNJ) que comprende un compuesto de la fórmula:**Fórmula** donde R1 es H o un alquilo, cicloalquilo, alquenilo, alcoxialquilo o aminoalquilo lineal o ramificado que contiene 1 - 12 átomos de carbono, un arilo, alquilarilo, heteroarilo o heteroarilalquilo que contiene 5 - 12 átomos de anillo, donde R1 está opcionalmente sustituido con uno o más -OH, -COOH, -Cl, -F,-CF3, -OCF3, -O-C(>=O)N-(alquilo)2; R2 es H; un alquilo, cicloalquilo, alquenilo, alquilarilo o alcoxialquilo lineal o ramificado, que contiene 1-9 átomos de carbono o arilo que contiene 5 - 12 átomos de carbono, en donde R2 está opcionalmente sustituido con -OH, -COOH, -CF3, -OCF3 o un anillo heterocíclico; en donde al menos uno de R1 y R2 no es H; o una sal farmacéuticamente aceptable del mismo, para el uso en el tratamiento de la enfermedad de Pompe, en donde el derivado de DNJ se usa para incrementar la actividad de una enzima α-glucosidasa (Gaa) lisosómica en una célula, a una concentración de o por debajo del valor de IC50 para la inhibición de Gaa intestinal; en donde dicho derivado de DNJ se ha de administrar como una monoterapia en un individuo que tiene enfermedad de Pompe; y en donde el derivado de DNJ no es 1-desoxinojirimicina o α-homonojirimicina; y en donde el derivado de DNJ se administra en una cantidad de 5 mg a 75 mg al día.
ES06770637T 2005-05-17 2006-05-17 Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados Active ES2572148T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68224105P 2005-05-17 2005-05-17
US72932905P 2005-10-21 2005-10-21
PCT/US2006/019406 WO2006125141A2 (en) 2005-05-17 2006-05-17 A method for the treatment of pompe disease using 1-deoxynojirimycin derivatives

Publications (1)

Publication Number Publication Date
ES2572148T3 true ES2572148T3 (es) 2016-05-30

Family

ID=37432167

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15153174T Active ES2705335T3 (es) 2005-05-17 2006-05-17 Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
ES06770637T Active ES2572148T3 (es) 2005-05-17 2006-05-17 Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES15153174T Active ES2705335T3 (es) 2005-05-17 2006-05-17 Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados

Country Status (12)

Country Link
US (3) US9181184B2 (es)
EP (4) EP3782655A1 (es)
JP (2) JP2008545657A (es)
KR (1) KR20080025373A (es)
AU (1) AU2006247065B8 (es)
BR (1) BRPI0612928A2 (es)
CA (1) CA2612538C (es)
ES (2) ES2705335T3 (es)
HK (1) HK1216230A1 (es)
IL (3) IL187461A (es)
MX (1) MX2007014470A (es)
WO (1) WO2006125141A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2814774C (en) 2003-01-31 2016-03-22 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
AU2004283631A1 (en) * 2003-10-29 2005-05-06 Genzyme Corporation Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
ES2709445T3 (es) 2006-05-16 2019-04-16 Amicus Therapeutics Inc Opciones de tratamiento para la enfermedad de Fabry
JP5241709B2 (ja) * 2006-05-24 2013-07-17 ユナイテッド セラピューティクス コーポレーション デオキシノジリマイシンおよびｄ−アラビニトールのアナログおよび使用方法
WO2008128098A1 (en) * 2007-04-13 2008-10-23 Amicus Therapeutics, Inc. Periodic acid schiff staining with detection in the infrared range
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
PT3470077T (pt) * 2008-02-12 2020-11-30 Amicus Therapeutics Inc Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas
JP2011512876A (ja) * 2008-03-12 2011-04-28 アミカス セラピューティックス インコーポレイテッド 特異的薬理シャペロンを用いたポンペ病の治療および代理マーカーを用いた治療の監視
JP2011517556A (ja) * 2008-03-12 2011-06-16 アミカス セラピューティックス インコーポレイテッド ポンペ病のための治療選択肢を診断し評価するための検定
WO2010015816A2 (en) * 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010056746A1 (en) * 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
AT507745B1 (de) * 2008-12-16 2012-01-15 Forschungsholding Tu Graz Gmbh Fluorophile glykosidasehemmer
WO2010096535A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Method for diagnosing pompe disease
US8466340B2 (en) 2009-02-18 2013-06-18 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
WO2010096764A1 (en) * 2009-02-23 2010-08-26 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
CN102625660B (zh) * 2009-02-24 2015-03-11 联合治疗公司 亚氨基糖以及治疗沙粒病毒感染的方法
ES2524361T3 (es) 2009-06-12 2014-12-05 United Therapeutics Corporation Iminoazúcares para su uso en el tratamiento de enfermedades por bunyavirus y togavirus
CN102625801B (zh) * 2009-09-04 2015-09-09 联合治疗公司 治疗痘病毒感染的方法
KR20120081990A (ko) * 2009-09-04 2012-07-20 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 이미노당 및 필로바이러스 질환의 치료 방법
BR112012004676A2 (pt) * 2009-09-04 2019-09-24 United Therapeutics Corp método de tratar infecções orotomixovirais.
CN103635230B (zh) 2011-05-12 2017-10-31 普罗蒂斯特斯治疗公司 蛋白内稳态调节剂
WO2013070953A1 (en) * 2011-11-08 2013-05-16 University Of Washington Lysosomal enzyme assay methods and compositions
JP2015504919A (ja) 2012-01-25 2015-02-16 プロテオステイシス セラピューティクス，インコーポレイテッド プロテアソーム活性を調節する化合物
KR20140135222A (ko) 2012-03-07 2014-11-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
PT2844279T (pt) * 2012-05-03 2021-03-11 Amicus Therapeutics Inc Esquema posológico para o tratamento da doença de pompe
WO2014017915A2 (en) 2012-07-27 2014-01-30 Universiteit Utrecht Holding B.V. Urea and guanidinium derivatives of iminosugars
CN102875450B (zh) * 2012-10-25 2015-04-08 上海丝绸集团股份有限公司 一种从桑叶中提取制备1-脱氧野尻霉素的工艺方法
WO2014110270A1 (en) 2013-01-09 2014-07-17 Amicus Therapeutics, Inc. Stable parenteral dnj compositions
PT3201320T (pt) 2014-09-30 2024-01-12 Amicus Therapeutics Inc Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados
WO2016073652A1 (en) * 2014-11-05 2016-05-12 Unither Virology, Llc Iminosugars useful for the treatment of viral diseases
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
DK3957320T5 (da) 2015-12-30 2024-08-05 Amicus Therapeutics Inc Forstærket syre-alfa-glucosidase til behandling af pompes sygdom
KR102444612B1 (ko) 2016-03-30 2022-09-21 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
MX2018011951A (es) 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.
TW202411239A (zh) * 2016-03-30 2024-03-16 美商阿米庫斯醫療股份有限公司 用於選擇高m6p重組蛋白之方法
EP3445451B1 (en) 2016-04-21 2021-08-18 Baylor College of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
JP2017195786A (ja) * 2016-04-25 2017-11-02 国立大学法人 熊本大学 細胞内酵素タンパク質の構造異常の正常化方法、細胞内酵素タンパク質の構造異常の検出方法、及び、遺伝性代謝病の治療方法ならびにその治療効果の予測・評価方法
AU2017260705A1 (en) * 2016-05-04 2018-11-22 Mirexus Biotechnologies Inc. Glycogen and phytoglycogen nanoparticles as immunosuppressive compounds, and compositions and methods of use thereof
TW201806597A (zh) 2016-07-19 2018-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症
EA202290114A1 (ru) * 2017-03-30 2022-03-29 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
CA3065147A1 (en) 2017-06-01 2018-12-06 Idorsia Pharmaceuticals Ltd Crystalline form of n-butyldeoxygalactonojirimycin
JP7551087B2 (ja) 2018-06-27 2024-09-17 キネタ， インコーポレイテッド プロテアソーム活性増強化合物
AU2019295765B2 (en) 2018-06-27 2024-08-29 Yumanity, Inc. Proteasome activity enhancing compounds
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
NL2021840B1 (en) 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
JP2022540632A (ja) 2019-07-09 2022-09-16 ジェネトン 糖原病（ｇｓｄ）の処置
EP4037682A4 (en) * 2019-10-04 2023-11-01 Academia Sinica METHODS OF TREATMENT OF PUMP DISEASE
JP2023507575A (ja) 2019-12-20 2023-02-24 コデクシス， インコーポレイテッド 操作された酸性アルファ－グルコシダーゼバリアント
EP3871687A1 (en) 2020-02-27 2021-09-01 eleva GmbH Enzyme replacement therapy for treating pompe disease
CN115867534A (zh) * 2020-05-07 2023-03-28 阿勒克图治疗公司 非溶酶体葡糖神经酰胺酶抑制剂及其用途
EP3944858A1 (en) 2020-07-30 2022-02-02 Beyond Batten Disease Foundation Combination product containing trehalose and miglustat for treating lysosomal diseases
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
WO2022227287A1 (zh) * 2021-04-25 2022-11-03 中南大学 Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US430307A (en) 1890-06-17 Reversible plow
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2834122A1 (de) 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
DE2853573A1 (de) 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
DE3038901A1 (de) 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
DE3611841A1 (de) 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
DE3737523A1 (de) 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US4985445A (en) * 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US4880917A (en) 1988-07-01 1989-11-14 Merrell Dow Pharmaceuticals Inc. Process for hydrolyzing 2,6-dideoxy-2,6-iminoheptononitrile derivatives using trifluoroacetic acid and dinitrogen tetroxide
US5310745A (en) 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) * 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
WO1992019195A1 (en) 1991-04-25 1992-11-12 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
DE69231736T2 (de) 1991-05-14 2001-10-25 The Immune Response Corp., Carlsbad Gerichtete abgabe von genen, die immunogene proteine kodieren
CA2103371C (en) 1991-06-05 2003-09-16 George Y. Wu Targeted delivery of genes encoding secretory proteins
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
US5401645A (en) 1992-03-16 1995-03-28 Monsanto Company Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US5798366A (en) 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5635493A (en) 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
AU1876095A (en) 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CA2230758A1 (en) 1995-09-08 1997-03-13 Genzyme Corporation Improved aav vectors for gene therapy
EP0959877A4 (en) 1996-04-10 2000-08-23 Univ California CORRECTION OF GENETIC DEFECTS USING CHEMICAL CAPS
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
EP1030839B1 (en) * 1997-11-10 2004-02-04 G.D. SEARLE & CO. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) * 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ATE410506T1 (de) 1998-12-07 2008-10-15 Genzyme Corp Behandlung der pompeschen krankheit
US6545021B1 (en) * 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
AUPP942599A0 (en) 1999-03-24 1999-04-15 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
JP2003505430A (ja) * 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
US6537785B1 (en) * 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6244113B1 (en) 1999-10-29 2001-06-12 University Of Alabama In Huntsville Method and apparatus for measuring microgravity acceleration
US6188045B1 (en) 2000-04-03 2001-02-13 Alto-Shaam, Inc. Combination oven with three-stage water atomizer
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
EP1974752B1 (en) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
AU2003284886A1 (en) 2002-10-21 2004-05-13 William E. Balch CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF Beta-GLUCOSIDASE
CA2814774C (en) 2003-01-31 2016-03-22 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
WO2005063706A1 (en) 2003-12-23 2005-07-14 Macrozyme Dnm B.V. Synthesis of nojirimycins
CA2556245A1 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
ATE465250T1 (de) 2004-02-10 2010-05-15 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
AU2007322123A1 (en) 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
WO2008112525A2 (en) 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
EP2252288A1 (en) 2007-11-21 2010-11-24 Summit Corporation Plc Treatment of protein folding disorders
JP2011517556A (ja) 2008-03-12 2011-06-16 アミカス セラピューティックス インコーポレイテッド ポンペ病のための治療選択肢を診断し評価するための検定
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010056746A1 (en) 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
WO2010118283A1 (en) 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
CN104409036B (zh) 2014-12-16 2017-01-11 上海天马微电子有限公司 一种显示面板和显示装置

Also Published As

Publication number Publication date
CA2612538A1 (en) 2006-11-23
IL209951A0 (en) 2011-02-28
AU2006247065B8 (en) 2012-07-12
EP2932982A1 (en) 2015-10-21
HK1216230A1 (zh) 2016-10-28
WO2006125141A3 (en) 2007-09-13
EP3441090A1 (en) 2019-02-13
EP3782655A1 (en) 2021-02-24
ES2705335T3 (es) 2019-03-22
EP2932982B1 (en) 2018-10-03
US11602528B2 (en) 2023-03-14
WO2006125141A2 (en) 2006-11-23
JP6043316B2 (ja) 2016-12-14
US20060264467A1 (en) 2006-11-23
IL249715A0 (en) 2017-02-28
US20160051528A1 (en) 2016-02-25
KR20080025373A (ko) 2008-03-20
US20180221357A1 (en) 2018-08-09
AU2006247065B2 (en) 2012-03-22
IL187461A (en) 2016-05-31
JP2014221759A (ja) 2014-11-27
EP1896083A4 (en) 2009-09-30
JP2008545657A (ja) 2008-12-18
IL209951A (en) 2017-01-31
EP1896083B1 (en) 2016-03-02
BRPI0612928A2 (pt) 2010-12-07
IL187461A0 (en) 2008-03-20
US9181184B2 (en) 2015-11-10
AU2006247065A1 (en) 2006-11-23
EP1896083A2 (en) 2008-03-12
CA2612538C (en) 2015-06-30
IL249715B (en) 2018-11-29
MX2007014470A (es) 2008-02-06

Similar Documents

Publication Publication Date Title
ES2572148T3 (es) Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
CN101677563A (zh) 5,6-二氢-1h-吡啶-2-酮化合物
PE20090770A1 (es) Derivados de benzoxazolona
ECSP066682A (es) Derivado novedoso de bencimidazol 2-heteroaril-substituido
HK1167607A1 (en) Quinoline derivative-containing pharmaceutical composition
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
MX2009010024A (es) Nuevo compuesto de adenina.
EA200401613A1 (ru) Лекарственное средство для лечения рака
CO5700757A2 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
EP1982982A4 (en) NEW COUMARINE DERIVATIVE WITH ANTITUM EFFECT
AR055563A1 (es) Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente
AR063458A1 (es) Derivados de piridina inhibidores de 11beta hsd1
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR074902A1 (es) Derivados de 1,2,4-oxadiazoles agonistas de receptores s1p1
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
PE20080714A1 (es) DERIVADOS HETEROCICLICOS COMO MODULADORES DE LA ACTIVIDAD DE LA ESTEARIL-CoA-DESATURASA
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
MXPA05013631A (es) Derivado heterociclico de metilsulfona.
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b
PE20080207A1 (es) DERIVADOS DE 1-N-AMINO-2-IMIDAZOLIDINONAS COMO INHIBIDORES DEL CANAL DE POTASIO Kv1.5
PE20050050A1 (es) Derivados de indolilo